Kymab: Old into newAntibody veteran David Chiswell, Interim CEO and Chair of Cambridge-based antibody developer Kymab, is taking over at the companys helm for good. Kymabs new old CEO is stepping down from his role … more ➔
Veterinary MandateThe EMAs Committee for Medicinal Products for Veterinary Use (CVMP) has unanimously appointed David Murphy from Ireland as its new Chair for the next three years. Murphy, a qualified veterinarian, … more ➔
Leading commercialisationTorsten Hombeck will take charge of the commercial activities and the general strategy of Promethera Biosciences. The Belgian cell therapy specialist appointed Hombeck as Chief Commercial and Strategy … more ➔
US growthPalma de Mallorca-based Sanifit, an expert for calcification disorders, has appointed Preston Klassen as its Chief Medical Officer. Klassen will also serve as President of Sanifits newly launched … more ➔
Queenly honourHarriet Fear, CEO of not-for-profit One Nucleus, has been appointed a Member of the Order of the British Empire in the Queens Birthday 2016 Honours List. The award recognises her services to the life … more ➔
Heading the second Cambridge siteUK biotech Bicycle Therapeutics has established US operations in Cambridge (MA). Rosamund Deegan, appointed to the newly established role of President and Chief Business Officer, will be responsible … more ➔
Serial founderManchester University spin-out C4X Discovery Holdings plc has a new CEO. UK biotech notable Clive Dix has taken over the helm of the UK drug discovery company. Dix joined C4XD as Non-Executive Chairman … more ➔
Generics visionaryAfter replacing several management positions over the last year, Polands leading generics producer Polpharma now also has a new head. Markus Sieger has succeeded Maurice Chagnaud as President of … more ➔
Pharma finance proResearch service provider Envigo has appointed Patricia Henahan as Chief Financial Officer. She has held similar roles at Eli Lilly, AstraZeneca, Medimmune and Hospira. more ➔
Oncology expertIn early May, Alfredo Zurlo took over the role of Chief Medical Officer at Berlin-based clinical-stage immuno-oncology company Glycotope. He joins from Mologen, where he held the position of CMO, too, … more ➔
